We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specificity. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
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Introduction
Despite numerous clinical trials, the benefit of adjuvant chemotherapy in the treatment of stage II colon cancer patients has never been proved in a randomized study.
In most meta-analyses, there is a trend toward a benefit of adjuvant chemotherapy, but statistical significance is not reached . Thus, this benefit seems to exist but, as it is slight, studies are not powerful enough to demonstrate it. This ambiguous situation is perfectly summarized by the conclusion of the 2004 recommendations of the American Society of Clinical Oncology (Benson et al., 2004) : 'Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer. Patients and oncologists y are justified in considering the use of adjuvant chemotherapy, particularly for those patients with high-risk stage II disease. y Patients with stage II disease should be encouraged to participate in randomized trials'.
Including all stage II colon cancer patients in a randomized trial is debatable. Even if a properly designed study, comprising thousands of patients, demonstrated a statistically significant benefit of adjuvant chemotherapy, it may not be logical to conclude that this treatment should be given to all stage II patients. Such a conclusion would not take into account that three-fourths of the patients are cured by surgery alone and would lead to administering to all patients a treatment that would be useful for only a few. Another more rational approach would be to identify a subgroup of patients at high risk of recurrence, thus more likely to benefit from adjuvant chemotherapy, and to include only these selected patients in a randomized trial. This presupposes finding accurate prognosis predictors (PPs) for stage II colon cancer patients.
There is increasing evidence that microarray gene expression profiling may accurately predict the postoperative prognosis of stage II colon cancer patients (Wang et al., 2004; Barrier et al., 2006) . Wang et al. (2004) identified, from a set of 38 patients, a 23-gene prognosis signature (PS) that was validated on an independent set of 36 patients, whereas we proposed a 30-gene PS (Barrier et al., 2006) . Even both PSs were totally different in terms of gene composition, the 23-gene PS was able to predict the prognosis of our patients (Barrier et al., 2006) . Tumor mRNA samples were the study material in both these reports. However, it is possible that non-neoplastic mucosa gene expression profiles might also be used for the same purpose. This hypothesis is supported by our findings on a previous series of 18-stage II and III colon cancer patients (Barrier et al., 2005) . The rationale for studying the nonneoplastic mucosa may be summarized as follows. There is an increasing evidence that interactions between stromal and cancer cells are a prerequisite for metastases to occur (Mueller and Fusenig, 2004) . However, it remains unclear whether this metastatic potential originates in cancer cells and/or in stromal compartments. Metastatic potential may be present from the start of the tumor (Bernards and Weinberg, 2002; Ramaswamy et al., 2003) . Accepting this theory, nonneoplastic mucosa on which the tumor has arisen may contain some helpful information.
The present study aimed to assess the possibility to build a microarray-based PP for stage II colon cancer patients using non-neoplastic mucosa gene expression profiles. Non-neoplastic mucosa mRNA samples from 24 patients, with homogeneous disease (stage II) and postoperative treatment (no adjuvant chemotherapy), but different outcomes (10 with metastatic recurrence, 14 with no recurrence) (Table 1), were profiled using the Affymetrix HGU133A GeneChip.
Results

Monte-Carlo cross-validation
A total of 1000 splits of patients into a training set (TS) and a validation set (VS) were considered. For each of these splits, a 70-gene was identified on the TS, and its prognosis prediction performance assessed on the corresponding VS.
The gene compositions of the 1000 70-gene PS were compared. The distribution of the number of selections for the set of 22 283 genes is given in Table 2 . The 1000 70-gene PS included a total of 2874 different genes; 752 of these 2874 genes (26.2%) were selected only once, whereas 2018 genes (70.2%) were selected less than 10 times; 157 genes (5.5%) were selected more than 100 times; and 15 genes (0.5%) more than 500 times. Only one gene was part of the 1000 70-gene PS.
The 1000 70-gene PS yielded an 81.8% mean prognosis prediction accuracy, a 73.0% mean sensitivity and a 87.1% mean specificity. Prognosis prediction accuracies of the 1000 PS are detailed in Table 3 ; 844 PS yielded a prognosis prediction accuracy of or greater than 75%.
Proposal of a 70-gene PS
The 70 informative genes that were identified based on all 24 patients are given in Tables 4 and 5 , with their t-statistics, their permutation-based raw P-values and their numbers of selections out of 1000 TS/VS splits by Monte-Carlo cross-validation (MCCV). Permutation-based raw P-values were computed using the Bioconductor R package multtest (function mt.maxT with B ¼ 100 000 permutations).
Of these 70 genes, 46 genes were overexpressed in patients who developed a recurrence (Table 4) , whereas the other 24 genes were overexpressed in patients who remained disease free for at least 5 years (Table 5) . Informative genes can be divided into three categories: (1) plasma membrane receptors with members of different signaling pathways and transcription factors; (2) proteins involved in cell growth and/or maintenance such as glucose metabolism, protein biosynthesis, transport and degradation; and (3) proteins involved in the immune response. The following membrane receptors were overexpressed in the mucosa of patients who recurred: solute carrier family 18; translocation protein 1; annexin 2; exostoses 2; ribophorin II; transmembrane protein 4; two G protein-coupled receptors involved in positive regulation of IkB kinase/NF-kB superfamily member 2. There were: CD24 antigen, a protein involved in the humoral immune response that is also a membrane receptor overexpressed on epithelial cancer cells; signal transducer and activator of transcription 2 that induces the JAK-STAT cascade; SPPL2b; potassium voltage channel shaker-related family beta member 1; basigin; and major histocompatibility complex Non-neoplastic mucosa in colon cancer A Barrier et al class I, C. As most of the cell-surface receptors are linked to signal transduction, an overexpression of some signal transducers and factors of transcription was also observed: WD40 protein ciao 1 that can interact with tumor suppressor proteins, and ADP-ribosylation factor-like 1 in patients who recurred, cyclin-dependent kinase (CDC2-like) 10, ankyring repeat and SOCS-box containing 13 in patients who did not recur. Among genes involved in immunity, two transcripts, CD24 and the major histocompatibility complex class I, C, were overexpressed in the mucosa of patients who did not recur. Two members of the forkhead-box transcription factors, forhead boxO1A and forkhead box J3, were overexpressed in patients who recurred and in those who did not recur, respectively.
Discussion
Two main conclusions can be drawn from the present study: the usefulness of a Monte-Carlo cross-validation design for an honest assessment of prognosis prediction performances, and the possibility to build a PP based on non-neoplastic mucosa gene expression profiles for stage II colon cancer patients. Studies aiming to propose a PP based on gene expression profiling are usually designed as follows: patients are randomly divided into a TS and a VS of equal or nearly equal sizes; a PS and corresponding PP are identified from the TS; the prognosis prediction accuracy of this PP is estimated on the VS. Reproducibility of results of these studies, based on single-split validation, is questionable. By repeating a high number of times (1000 in the present study), the initial random split of patients into a TS and a VS, and applying to each pair of TS/VS the same algorithm, Monte-Carlo cross-validation provides a way to appreciate reproducibility of results (Dudoit and van der Laan, 2005) . In the present study, results, both in terms of prognosis prediction performances and PS composition, greatly varied between random splits of patients. This variability, which has been previously reported (Dudoit and van der Laan, 2005; Michiels et al., 2005; Barrier et al., 2006) , outlines the weakness of studies based on a unique split of patients. The range of observed prognosis prediction accuracies for the 1000 PP was wide: from 37.5 to 100%. Thus, it appears hazardous to conclude to the efficiency of a PP based on a unique estimate as it is performed in single-split-validation studies. PS composition was highly unstable between random splits of patients, as 2874 genes were included in the 1000 70-gene PS. Of these, more than 70% were included in 10 PS or less, 5.5% in 100 PS or more, 0.5% in 500 PS or more and only one gene was part of all the 1000 PS. This strongly suggests that many PP with similar performances do exist.
In the present study, the following two main choices were made for building PPs: (i) the number of genes to Non-neoplastic mucosa in colon cancer A Barrier et al include in the PS was set to 70, based on previous results (Barrier et al., 2005) ; (ii) PPs were constructed using diagonal linear discriminant analysis (DLDA), as DLDA was shown to be competitive with more complex techniques (Dudoit et al., 2002; Dudoit and Fridlyand, 2003) . Both these choices were somewhat arbitrary and many other gene selection methods and classifiers could have been used. To determine the influence of our choices on results, we have reproduced exactly the same MCCV analysis as above with 70-gene t-statistic-based PSs and nearest neighbor classifiers (Dudoit et al., 2002) , and with DLDA based on PSs including various numbers of genes (from 10 to 300) (Supplementary material). The results of these supplementary analyses suggest a moderate influence of the length of the PS and the choice of classifier on PP performance. The main originality of the present study is to have considered non-neoplastic mucosa samples for gene expression profiling, instead of tumor samples (Wang et al., 2004; Arango et al., 2005; Barrier et al., 2006) . Non-neoplastic colonic mucosa gene expression profiles have already been studied, but only to compare them to tumor profiles (Alon et al., 1999; Kitahara et al., 2002; Notterman et al., 2002; Zou et al., 2002) . The reason was to confirm the results we have observed on a smaller series of patients with heteregeous stages of disease (II and III) and postoperative treatments (chemotherapy or no chemotherapy) (Barrier et al., 2005) . Here, we have included patients with homogeneous stage of disease (II) and postoperative treatment (no adjuvant chemotherapy), and with a sufficient length of follow-up (at least 60 months in the disease-free group).
Results clearly suggest the possibility to build an accurate PP based on non-neoplastic mucosa gene expression profiling for stage II colon cancer patients. For the 1000 PPs, the mean prognosis prediction accuracy was 81.8%, whereas the mean sensitivity and mean specificity were 73.0 and 87.1%, respectively. For 844 of the 1000 PPs, the PP accuracy was equal to or greater than 75.0%.
As the possibility to build an accurate PP based on tumor gene expression profiling has already been proved (Wang et al., 2004; Barrier et al., 2006) , the question of whether one should better use non-neoplastic mucosa or tumor samples immediately arises. No definite answer can be given at this point. A theoretical advantage of non-neoplastic mucosa is that it represents a homogeneous pathological sample, whereas the tumor includes both tumoral and non-tumoral cells. In addition, non-neoplastic mucosa-based PPs seem to be slightly more accurate: in a previous study that included stages II and III colon cancer patients with paired samples for each patient, the estimated accuracies of non-neoplastic mucosa-based and tumor-based PPs were 83 and 78%, respectively (Barrier et al., 2005) ; in another study that assessed tumor-based PPs for stage II patients, using the same Monte-Carlo cross-validation design, the mean prognosis prediction accuracy was 76.1% (Barrier et al., 2006) , compared to 81.8% in the present study. Conversely, non-neoplastic mucosa-based predictors seem to have a lower sensitivity than tumor-based predictors: in the present study, the mean prognosis prediction sensitivity was 73.0%, compared to 85.1% in our previous series (Barrier et al., 2006) . Interestingly, genes included in the proposed predictor are not cancer genes or genes encoding elements of the adhesion system, migration or proteolysis, but rather suggest branching signal transduction pathways with possible extensive networks between individual pathways and between cells themselves. For example, in the nonneoplastic mucosa of patients who recurred, we have observed an overexpression of two membrane receptors, annexin 2 and transmembrane protein 4, previously shown to be involved in tumor invasion (Mazzocca et al., 2002; Hashida et al., 2003; Tanaka et al., 2004) . Conversely, in the mucosa of patients who did not recur after a follow-up of 5 years, we have observed an increased expression of some genes already reported to induce tumor cell invasion: basigin, known to stimulate production of matrix metalloproteinases by fibroblasts, a member of transmembrane protein 4 and CD24 (Kanekura et al., 2002; Kristiansen et al., 2004) . CD24 is a mucin-like cell-surface molecule on human neutrophils, pre-lymphocytes and many epithelial tumors. Its overexpression in some epithelial tumors, frequently associated with a high tumor grade, has suggested its prognostic value as a routine marker (Kristiansen et al., 2004) . However, an absence of expression of CD24 mRNA has also been observed in invasive mammary carcinoma-derived cells compared to non-invasive cells (Schindelmann et al., 2002) . The role of CD24 in the dissemination of tumor cells could be due to different pathophysiological processes according to its cellular localization. Our results emphasize that the immune response, to promote the survival or the death of malignant cells, is not restricted to immune cells that infiltrate tumors (Li et al., 2004) . They also suggest that the tumor microenvironment and the host's immune response are of major importance in tumor progression as recently shown (Pages et al., 2005) . The recruitment of cells distant from the primary tumor could constitute a possible mechanism for the presence of lymph-node metastases in some solid tumors such as colorectal cancers. The overexpression of genes coding for membrane receptors coupled with signal transduction, such as G-protein-coupled receptor and protein kinases, transcription factors and members of cellular proteolysis systems, such as the Cop9 signalosome and 26S proteasome, suggests an important crosstalk between cells, probably connecting the initial events, for example, activation of receptors, to the activation of gene expression in the nucleus. The activation of signaling pathways has been already shown to play a central function in invasion-related cellular activities determining the cells response to extrinsic or intrinsic modulators (Barbier et al., 2001) . This 'conversation' may be relayed by host cells distant from the primary tumors, these cells presenting normal phenotype and thus allowing an adaptated signaling.
In conclusion, the present study suggests the possibility to use the non-neoplastic mucosa gene expression profiles to predict the postoperative prognosis of stage II colon cancer patients. By contrast to tumor-based PPs, non-neoplastic mucosa-based PPs seem to be more specific than sensitive, that is, more able to detect patients with a good prognosis. Relative performances of both types of predictors remain to be compared on larger series of patients before proposing a clinical application. The present study also raises questions regarding the role of the so-called 'normal mucosa' surrounding the tumor. Several questions remain to be elucidated. One of these is to determine whether normal cells distant from the tumors are contacted to stop and repair or to help the cancer cell invasion.
Materials and methods
Patients and samples
Twenty-four patients (13 men, 11 women, mean age ¼ 66 years) operated on for a stage II colon adenocarcinoma in the Department of Digestive Surgery of the Hospital Tenon between 1996 and 2000 were included in this study. The main patients' and tumors' characteristics are given in Table 1 . None of these 24 patients received any adjuvant chemotherapy. Patients were evaluated at 3-month intervals for the first postoperative year and at 6-month intervals thereafter (clinical examination, chest X-ray, liver ultrasound or computed tomography scan). Ten patients developed a liver metastasis in the follow-up. The mean time to recurrence was 30.1 months (range ¼ 10-55 months). The other 14 patients remained disease free for at least 60 months, the mean follow-up being 72.2 months (range ¼ 62-92 months).
Adjacent non-neoplastic colon mucosa samples (distance between 5 and 10 cm from the gross tumor limit) were collected at time of surgery, with patients' informed consent, and were immediately stored in liquid nitrogen. Samples were reviewed by a pathologist to check the absence of tumor cells. RNA samples were extracted and hybridized to Affymetrix HGU133A GeneChips according to previously described protocol (Barrier et al., 2005) .
Starting from the 24 CEL files, gene expression measures were computed using the Robust multichip average method implemented in the bioconductor package rma (http://www. bioconductor.org) and described by Bolstad et al. (2005) . Gene expression measures are available at the following addresses: http://www.u707.jussieu.fr/boelle/genechips/index.html and http://www.stat.berkeley.edu/Bsandrine.
Data analysis
A MCCV was used (Dudoit and van der Laan, 2005) . The 24 patients were repeatedly and randomly divided into 1000 TSs of size 16 and corresponding VS of size 8. For a given split of patients into a TS and a VS, a 70-gene PP was built on the TS and its performance assessed on the VS as follows.
Step 1: Gene expression measures were compared in recurrent and non-recurrent TS patients by computing twosample equal-variance t-statistics for each of the 22 283 genes. A PS was defined in terms of the expression measures of the 70 genes with the largest absolute t-statistics.
Step 2: A PP was constructed by applying DLDA to the 70-gene PS of the TS patients (Dudoit et al., 2002; Dudoit and Fridlyand, 2003) .
Step 3: The 70-gene PP from
Step 2 was applied to predict the prognoses of the VS patients.
Step 4: The predicted and actual prognoses (recurrence or no recurrence) of VS patients were compared to obtain the following three measures of prognosis prediction performance: accuracy (proportion of correctly predicted prognoses), sensitivity (proportion of correctly predicted recurrences) and specificity (proportion of correctly predicted non-recurrences).
The gene compositions of the 1000 70-gene PS were compared. Distributions of prognosis prediction accuracy, sensitivity and specificity for the 1000 70-gene PS were obtained.
An overall 70-gene PS was identified based on all 24 patients, by comparing the expression measures of recurrent and non-recurrent patients for each of the 22 283 genes using two-sample equal-variance t-statistics and selecting the 70 genes with the largest absolute t-statistics. 
